ADMA Biologics (ADMA) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 2, 2026, will be held virtually to maximize shareholder participation and accessibility.

• Shareholders as of April 8, 2026, are entitled to vote on key proposals, including director elections, auditor ratification, and executive compensation.

• Board unanimously recommends voting in favor of all proposals.

Voting matters and shareholder proposals

• Proposals include electing two Class I directors for terms expiring in 2029, ratifying KPMG LLP as independent auditor for 2026, and a non-binding advisory vote on executive compensation.

• Voting can be done online, by phone, mail, or during the virtual meeting; proxy materials are available electronically or by request.

• Board recommends voting "FOR" all proposals.

Board of directors and corporate governance

• Board consists of seven directors, five of whom are independent under Nasdaq standards.

• Board is divided into three classes with staggered three-year terms; current nominees are Alison C. Finger and Eduardo Rene Salas.

• Committees include Audit, Compensation, and Governance and Nominations, all composed solely of independent directors.

• Board leadership separates CEO and Chairman roles to enhance oversight and accountability.

• Succession planning for executive roles is reviewed annually.